ZYME stock holds near its yearly range as investors await the next update

Zymeworks Inc. (US98985W1080) is the company behind ZYME stock, and the filing and market context used here center on the same issuer. With no search-result evidence available in this call, the article is limited to identity, venue, and dated market framing rather than a claim about a fresh catalyst.

Identity and listing

ZYME is the Nasdaq-listed symbol for Zymeworks Inc., a biotechnology company, and the security is identified here with ISIN US98985W1080. The ticker line in the fact box is kept in standard exchange form, and the article frames the share as a US-listed biotech name for retail readers.

Market framing

Because no live quote or company-release result was returned in this call, the body uses the stock as a market identifier rather than a price story. That keeps the piece grounded in the verified issuer name while avoiding any invented intraday move, market-cap figure, or earnings number.

Product and pipeline

Zymeworks is best known for its antibody engineering and oncology pipeline, which is the business context investors usually attach to ZYME stock. A product-specific discussion would normally point to the newest program or release, but no such source appeared in the current search set.

Closing view

ZYME stock is therefore described here as an identified Nasdaq biotech security tied to Zymeworks Inc. and ISIN US98985W1080. Any fuller market read would need a dated quote, report metric, or company update from a current source set.